Scientists aimed to determine whether human bone marrow mesenchymal stem cells can differentiate into biliary epithelial cells in vitro and in vivo and to clarify the role of delta-like ligand 4 (DLL4) in restoring damaged liver by enhancing cholangiocyte differentiation.
[Stem Cell Research]
1254621 SBPHFEGZ items 1 apa default asc 1
Investigators demonstrated 89Zr-oxine labeling and PET-CT imaging as a potential clinical solution for non-invasively tracking MSCTRAIL biodistribution
[Stem Cell Research & Therapy]
1254621 BHJVWTJM items 1 apa default asc 1
AVROBIO, Inc. announced that the first patient has been dosed in the company’s GuardOne clinical trial, a Phase I/II investigational study evaluating AVR-RD-02 for Gaucher disease type 1.
Celixir announced an update to its ongoing clinical programme with lead therapeutic candidate CLXR-001.
[Celixir (GlobeNewswire, Inc.)]
Adverum Biotechnologies, Inc. announced the completion of patient dosing in Cohort 4 of OPTIC, a Phase I clinical trial, assessing a single intravitreal injection of ADVM-022 in patients with wet age-related macular degeneration.
[Adverum Biotechnologies, Inc.]
Investigators studied if imlifidase could eliminate anti-adeno-associated virus antibodies in the context of gene therapy.
1254621 4AT667NS items 1 apa default asc 1
A new US immigration policy, which threatens to revoke visas for certain international students if they are not taking in-person classes, is stirring panic and confusion and causing some universities to push back with lawsuits.
Since higher education institutions ended in-person classes in March due to the COVID-19 pandemic, there has been uncertainty over what classes will look like in the fall. Universities will soon have to come up with an answer.
The new director of the National Science Foundation (NSF), Sethuraman “Panch” Panchanathan, is familiar with the dark clouds over the agency. His boss, President Donald Trump, keeps proposing big cuts to NSF’s budget. Two recent executive orders on immigration make it harder for foreign scientists—who make up a sizeable share of the U.S. research enterprise—to enter the country.
Scientists demonstrated that simultaneous targeting of an additional antigen—here, G protein-coupled receptor class-C group-5 member-D (GPRC5D)—can prevent B-cell maturation antigen escape–mediated relapse in a model of multiple myeloma. To identify an optimal approach, they compared subtherapeutic doses of different forms of dual-targeted cellular therapy.
[Blood Cancer Discovery]
1254621 7TWXKZ45 items 1 apa default asc 1
Cabaletta Bio, Inc. announced they have signed a research and collaboration agreement to accelerate development of next-generation CAAR T cell therapies for patients with B cell-mediated autoimmune diseases.
[Calbetta Bio, Inc.]